- Home
- TLSI vs TEAF Comparison
TLSI vs TEAF Comparison
Compare TLSI & TEAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- TEAF
- Stock Information
- Founded
- TLSI 2010
- TEAF 2017
- Country
- TLSI United States
- TEAF United States
- Employees
- TLSI N/A
- TEAF N/A
- Industry
- TLSI Medical Specialities
- TEAF Trusts Except Educational Religious and Charitable
- Sector
- TLSI Health Care
- TEAF Finance
- Exchange
- TLSI Nasdaq
- TEAF Nasdaq
- Market Cap
- TLSI 124.9M
- TEAF 174.8M
- IPO Year
- TLSI N/A
- TEAF N/A
- Fundamental
- Price
- TLSI $4.69
- TEAF $11.95
- Analyst Decision
- TLSI Strong Buy
- TEAF
- Analyst Count
- TLSI 6
- TEAF 0
- Target Price
- TLSI $11.75
- TEAF N/A
- AVG Volume (30 Days)
- TLSI 36.4K
- TEAF 56.1K
- Earning Date
- TLSI 11-14-2024
- TEAF 01-01-0001
- Dividend Yield
- TLSI N/A
- TEAF 9.20%
- EPS Growth
- TLSI N/A
- TEAF N/A
- EPS
- TLSI N/A
- TEAF N/A
- Revenue
- TLSI $26,891,000.00
- TEAF N/A
- Revenue This Year
- TLSI $60.96
- TEAF N/A
- Revenue Next Year
- TLSI $53.65
- TEAF N/A
- P/E Ratio
- TLSI N/A
- TEAF N/A
- Revenue Growth
- TLSI 67.90
- TEAF N/A
- 52 Week Low
- TLSI $3.50
- TEAF $11.11
- 52 Week High
- TLSI $10.42
- TEAF $13.30
- Technical
- Relative Strength Index (RSI)
- TLSI 51.68
- TEAF 35.01
- Support Level
- TLSI $4.72
- TEAF $11.84
- Resistance Level
- TLSI $5.32
- TEAF $12.21
- Average True Range (ATR)
- TLSI 0.31
- TEAF 0.13
- MACD
- TLSI 0.01
- TEAF 0.01
- Stochastic Oscillator
- TLSI 47.52
- TEAF 37.04
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About TEAF Ecofin Sustainable and Social Impact Term Fund
Tortoise Essential Assets Income Term is a US-based non-diversified, closed-end management investment company. Its investment objective is to provide common shareholders with a high level of total return with an emphasis on current distributions.